PL440067A1 - Anti-FOLR1 antibody and its application in medicine - Google Patents

Anti-FOLR1 antibody and its application in medicine

Info

Publication number
PL440067A1
PL440067A1 PL440067A PL44006721A PL440067A1 PL 440067 A1 PL440067 A1 PL 440067A1 PL 440067 A PL440067 A PL 440067A PL 44006721 A PL44006721 A PL 44006721A PL 440067 A1 PL440067 A1 PL 440067A1
Authority
PL
Poland
Prior art keywords
antibody
application
medicine
application relates
folr1 antibody
Prior art date
Application number
PL440067A
Other languages
Polish (pl)
Other versions
PL244962B1 (en
Inventor
Sebastian Dominik Pawlak
Róża SAWICKA
Original Assignee
Adamed Pharma Spółka Akcyjna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adamed Pharma Spółka Akcyjna filed Critical Adamed Pharma Spółka Akcyjna
Priority to PL440067A priority Critical patent/PL244962B1/en
Publication of PL440067A1 publication Critical patent/PL440067A1/en
Publication of PL244962B1 publication Critical patent/PL244962B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Zgłoszenie dotyczy przeciwciała, które wiąże się z receptorem FOLR1 i wykazuje aktywność cytotoksyczności komórkowej zależnej od przeciwciał. Dokładniej zgłoszenie dotyczy przeciwciała anty-FOLR1 i jego koniugatów ze związkami czynnymi farmakologicznie. Ponadto zgłoszenie dotyczy kompozycji farmaceutycznych zawierających takie przeciwciała i ich koniugaty.The application relates to an antibody that binds to the FOLR1 receptor and exhibits antibody-dependent cellular cytotoxicity activity. More specifically, the application relates to the anti-FOLR1 antibody and its conjugates with pharmacologically active compounds. Furthermore, the application relates to pharmaceutical compositions comprising such antibodies and their conjugates.

PL440067A 2021-12-31 2021-12-31 Anti-FOLR1 antibody and its use in medicine PL244962B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL440067A PL244962B1 (en) 2021-12-31 2021-12-31 Anti-FOLR1 antibody and its use in medicine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL440067A PL244962B1 (en) 2021-12-31 2021-12-31 Anti-FOLR1 antibody and its use in medicine

Publications (2)

Publication Number Publication Date
PL440067A1 true PL440067A1 (en) 2023-07-03
PL244962B1 PL244962B1 (en) 2024-04-08

Family

ID=87000512

Family Applications (1)

Application Number Title Priority Date Filing Date
PL440067A PL244962B1 (en) 2021-12-31 2021-12-31 Anti-FOLR1 antibody and its use in medicine

Country Status (1)

Country Link
PL (1) PL244962B1 (en)

Also Published As

Publication number Publication date
PL244962B1 (en) 2024-04-08

Similar Documents

Publication Publication Date Title
CY1124844T1 (en) PHARMACEUTICAL ANTIBODY PREPARATION
MX2020004691A (en) Hydrophilic linkers for antibody drug conjugates.
CL2016002585A1 (en) Immunoconjugate comprising an antigen-binding protein that binds to maturation antigen of lymphocytes b (bcma) and a cytotoxic agent, pharmaceutical composition and its use (divisional application 201303373)
MX2022002592A (en) ANTIBODY-DRUG CONJUGATE COMPRISING AN ANTIBODY AGAINST THE ORPHAN RECEPTOR 1 GENE SIMILAR TO HUMAN RECEPTOR TYROSINE KINASE (ROR1) AND USE THEREOF.
EP4209513A4 (en) BISPECIFIC ANTI-VEGF-ANTI-PD-L1 ANTIBODY, PHARMACEUTICAL COMPOSITION THEREOF AND USES THEREOF
EA201890130A1 (en) ANTIBODY TO HUMAN TRANSFERRIN RECEPTOR PENETRATING THROUGH THE HEMATOENCEPHALIC BARRIER
IL313805A (en) Antibody drug conjugates
PH12016500349B1 (en) Anti-prlr antibodies and uses thereof
PH12021551265A1 (en) Pharmaceutical compositions comprising anti-191p4d12 antibody drug conjugates and methods of use thereof
MX2016007865A (en) Cytotoxic peptides and conjugates thereof.
MX2022005221A (en) ERIBULIN ANTI-MESOTHELIN ANTIBODY AND DRUG CONJUGATES AND METHODS OF USE.
PL410219A1 (en) A composition comprising a drug conjugate comprising calicheamicin derivatives and an antibody, and a pharmaceutical composition containing it
EA201290123A1 (en) PRODUCTS OF MERGERS AND CONJUGATES OF MEDICINES WITH INCREASED PERIOD OF SEMI-EXTRACT
EA200970469A1 (en) ANTIBODY-AGONISTS OF THE TRKB RECEPTOR AND THEIR APPLICATION
WO2020236841A3 (en) Antibody drug conjugates having linkers comprising hydrophilic groups
JOP20230109A1 (en) Heavy chain antibodies bind to the alpha-folate receptor
EP4410835A4 (en) ANTI-LAG3 ANTIBODIES, PHARMACEUTICAL COMPOSITION AND USE
DK3811979T3 (en) Pharmaceutical composition with anti-HER2 antibody drug conjugate
SA520420225B1 (en) cMET Monoclonal antibody drug conjugates and their uses
MX2024004048A (en) Anti-cd37 antibody-drug conjugate.
IL317447A (en) Antibody drug conjugates
IL316653A (en) Antibody drug conjugates
ZA202211123B (en) Drug antibody conjugates
PL440011A1 (en) Anti-FOLR1 nanobody and its application in medicine
EP4093774A4 (en) CONDITIONALLY ACTIVE ANTI-HER2 ANTIBODIES, ANTIBODY FRAGMENTS, THEIR IMMUNOCONJUGATES AND RELATED USES